Company Description
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally.
The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies.
It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits.
It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment.
In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation.
Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery.
The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
Country | United States |
IPO Date | Aug 4, 2000 |
Industry | Medical - Devices |
Sector | Healthcare |
Employees | 9,707 |
CEO | Dr. Frank H. Laukien Ph.D. |
Contact Details
Address: 40 Manning Road Billerica, Massachusetts United States | |
Website | https://www.bruker.com |
Stock Details
Ticker Symbol | BRKR |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001109354 |
CUSIP Number | 116794108 |
ISIN Number | US1167941087 |
Employer ID | 04-3110160 |
SIC Code | 3826 |
Key Executives
Name | Position |
---|---|
Dr. Burkhard Prause Ph.D. | President and Chief Executive Officer of Bruker Energy & Supercon Technologies, Inc. |
Dr. Frank H. Laukien Ph.D. | Chairman, Chief Executive Officer & President |
Gerald N. Herman CPA | Executive Vice President & Chief Financial Officer |
Dr. Falko Busse Ph.D. | President of Bruker BioSpin Group |
Dr. Mark R. Munch Ph.D. | Corporate Executive Vice President and President of Bruker Nano Group & Corporate |
J. Brent Alldredge J.D. | General Counsel & Secretary |
Juergen Srega | President of Bruker CALID Group & Bruker Daltonics Division |
Justin Joseph Ward | Senior Director of Investor Relations & Corporate Development |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 03, 2024 | 4 | Filing |
Nov 25, 2024 | 4 | Filing |
Nov 19, 2024 | 4 | Filing |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Nov 05, 2024 | 8-K | Current Report |
Aug 16, 2024 | 4 | Filing |
Aug 13, 2024 | 4 | Filing |